FIELD: medicine; psychiatry.
SUBSTANCE: group of inventions can be used in treating major depressive disorder. Methods of the invention involve intranasal administration of a pharmaceutical composition containing esketamine to a human patient.
EFFECT: use of inventions enables to reduce the intensity of symptoms of major depressive disorder, including suicidal ideation.
30 cl, 119 dwg, 172 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ESKETAMINE FOR TREATING DEPRESSION | 2018 |
|
RU2822657C2 |
| METHODS OF TREATMENT OF BIPOLAR DISORDER | 2011 |
|
RU2653408C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| TREATMENT OF BIPOLAR DISORDERS AND ACCOMPANYING SYMPTOMS | 2005 |
|
RU2403039C2 |
| NORADRENERGIC AND SPECIFICALLY SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, ITS PRODUCTION AND APPLICATION METHOD | 2020 |
|
RU2775772C2 |
| METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHOEA | 2011 |
|
RU2597746C2 |
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR TREATMENT OF AGITATION IN DEMENTIA | 2020 |
|
RU2838188C2 |
